Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SanofiXSWX:SAN 91 EV-to-OCF is 9.20 as of Aug. 13, 2026, which is 30% below its 10-year median of 13.23. GuruFocus rates XSWX:SAN with a GF Score™ of 91/100 and a GF Value™ of CHF103.32. The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Sanofi ranks better than 55.17% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sanofi's Enterprise Value is CHF101,067 Mil.
Sanofi's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was CHF10,989 Mil. Therefore, Sanofi's EV-to-OCF for today is 9.20.
The historical rank and industry rank for Sanofi's EV-to-OCF or its related term are showing as below:
XSWX:SAN'
s EV-to-OCF Range Over the Past 10 Years
Min: 9.12 Med: 13.23 Max: 23.63
Current: 9.12
During the past 13 years, the highest EV-to-OCF of Sanofi was 23.63. The lowest was 9.12. And the median was 13.23.
XSWX:SAN's EV-to-OCF is ranked better than 55.17% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.145
vs XSWX:SAN: 9.12
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-13), Sanofi's stock price is CHF73.20.
Sanofi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF3.032. Therefore, Sanofi's PE Ratio (TTM) for today is 24.14.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sanofi's share price for today is CHF73.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF3.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sanofi EV-to-OCF Related Terms
Sanofi EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sanofi's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Sanofi's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sanofi's EV-to-OCF falls into.
Sanofi's current Enterprise Value is CHF101,067 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was CHF10,989 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi (XSWX:SAN) has a EV-to-OCF of 9.20 as of Aug. 13, 2026. This is 30% below median its historical median of 13.23. Over the past decade, Sanofi's EV-to-OCF has ranged from 9.12 to 23.63. According to the industry distribution chart, Sanofi ranks #451 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 44.8%.
Is Sanofi's EV-to-OCF too high?
Sanofi's current EV-to-OCF of 9.20 is 30% below median its 10-year median of 13.23. Over the past 10 years, this metric has ranged from a low of 9.12 to a high of 23.63. The Drug Manufacturers industry median EV-to-OCF is 11.15. Sanofi's value of 9.20 is 17.5% below this industry median. Based on the distribution chart, Sanofi ranks #451 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanofi has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #451 out of 1006 companies for EV-to-OCF. This puts Sanofi in the upper half of its industry. The industry median EV-to-OCF is 11.15. Sanofi's value of 9.20 is 17.5% below this benchmark. Historically, Sanofi's own EV-to-OCF has ranged from 9.12 to 23.63 over the past decade. While the company's 10-year median is 13.23 vs. the industry median of 11.15, Sanofi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.15, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi's current EV-to-OCF of 9.20 is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current EV-to-OCF is 9.20, which is 30% below median its own 10-year median of 13.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current EV-to-OCF of 9.20. The stock's GF Value™ is CHF103.32, compared to a current price of CHF73.20 — trading 29.2% below its estimated fair value. The current EV-to-OCF is 9.20, which is 30% below median its 10-year median of 13.23 and 17.5% below the Drug Manufacturers industry median of 11.15. Sanofi's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current EV-to-OCF is 9.20 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (XSWX:SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of CHF73.20 is trading 29.2% below its estimated GF Value™ of CHF103.32.
Key valuation signals for XSWX:SAN:
EV-to-OCF: 9.20 (30% below median its 10-year median of 13.23)
GF Value™: CHF103.32 vs. price of CHF73.20 (29.2% below fair value)
Industry Position: 17.5% below the Drug Manufacturers median (#451 of 1006)
No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
91GF Score
Get the complete analysis for XSWX:SAN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SAN has been successfully added to your 
